Abstract
The discovery of HM74a as a high affinity receptor for nicotinic acid has opened up new areas for investigation. Since its discovery, several new chemical entities have been reported as HM74a agonists. One of them, MK-0354, has been tested in phase II studies, but despite significant decreases in Free Fatty Acid levels with absence of flushing events in clinical studies, it failed to demonstrate effects on LDL-Cholesterol, Triglycerides and HDLCholesterol. These surprising results lead to questions about the reality of HM74a as the unique receptor responsible for the lipid modulating effects of nicotinic acid. This review summarizes these recent developments, and the novel HM74a antagonist structures recently published.
Keywords: HM74a, GPR109a, PUMA-G, Nicotinic Acid, HDL-Cholesterol
Current Topics in Medicinal Chemistry
Title: HM74a Agonists: Will they be the New Generation of Nicotinic Acid?
Volume: 9 Issue: 5
Author(s): Paul Martres
Affiliation:
Keywords: HM74a, GPR109a, PUMA-G, Nicotinic Acid, HDL-Cholesterol
Abstract: The discovery of HM74a as a high affinity receptor for nicotinic acid has opened up new areas for investigation. Since its discovery, several new chemical entities have been reported as HM74a agonists. One of them, MK-0354, has been tested in phase II studies, but despite significant decreases in Free Fatty Acid levels with absence of flushing events in clinical studies, it failed to demonstrate effects on LDL-Cholesterol, Triglycerides and HDLCholesterol. These surprising results lead to questions about the reality of HM74a as the unique receptor responsible for the lipid modulating effects of nicotinic acid. This review summarizes these recent developments, and the novel HM74a antagonist structures recently published.
Export Options
About this article
Cite this article as:
Martres Paul, HM74a Agonists: Will they be the New Generation of Nicotinic Acid?, Current Topics in Medicinal Chemistry 2009; 9 (5) . https://dx.doi.org/10.2174/156802609788340814
DOI https://dx.doi.org/10.2174/156802609788340814 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood Coagulation and the Risk of Atherothrombosis
Current Genomics High Serum Alkaline Phosphatase Levels in Relation to Multi-Cerebral Microbleeds in Acute Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease
Current Neurovascular Research Gene Therapy for Osteoinduction
Current Gene Therapy Electrocardiographic and Cardiac Autonomic Indices - Implications of Sex-Specific Risk Stratification in Women After Acute Myocardial Infarction
Current Pharmaceutical Design Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Need for Ongoing Anti Arrhythmic Drugs After Ablation of Atrial Fibrillation. Review
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot Topic Biomarkers, Molecular Imaging, and Novel Therapies of Cancer]
Current Molecular Medicine Macrophage Activation in Atherosclerosis: Pathogenesis and Pharmacology of Plaque Rupture
Current Vascular Pharmacology Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Editorial (Thematic Issue: GPCR-Targeted Drug Development)
Current Drug Targets Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design TP Receptor as a Therapeutic Target in Atherosclerosis and Related Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Endothelial Dysfunction in Metabolic Diseases: Role of Oxidation and Possible Therapeutic Employment of N-acetylcysteine
Current Medicinal Chemistry The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Quality Assessment of Wheat Bread with Microbial Transglutaminase Supplemented with Hull-Less Barley Flour
Current Nutrition & Food Science The Endothelium and Platelets in Cardiovascular Disease: Potential Targets for Therapeutic Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Anti-inflammatory and Antioxidant Agents from Salvia Genus (Lamiaceae): An Assessment of the Current State of Knowledge
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin
Current Topics in Medicinal Chemistry